#United States #Chicago #Regor Therapeutics #RGT-075 #ADA Conference

Regor Therapeutics to Present Innovative Data on RGT-075

Regor Therapeutics Group recently announced its participation at the 85th Scientific Sessions of the American Diabetes Association (ADA), scheduled for June 20-23, 2025, in Chicago. The company, recognized for its commitment to developing advanced clinical-stage biotechnology solutions, will present significant findings from its Phase 2A trial involving RGT-075, a promising candidate for obesity management.

Overview of RGT-075

RGT-075 is not just any treatment; it’s a small molecule oral GLP-1 receptor agonist designed for once-daily administration. This innovation underscores Regor’s mission to tackle metabolic diseases, including obesity and type 2 diabetes mellitus, particularly in patients facing weight-related health issues. The previously completed Phase 1 studies indicated RGT-075's potential for effective weight reduction, rallying optimism around its tolerability and safety profile.

The ADA presentation will specifically offer insights into the efficacy of RGT-075, showcasing data collected in a randomized, placebo-controlled Phase 2A Proof-of-Concept study conducted over twelve weeks. This trial involved adults diagnosed with obesity or overweight, assessing the medication's ability to induce weight loss while monitoring associated health risks.

Presentation Details at ADA 2025

The details of the poster presentation are as follows:

• - Title: First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study
• - Date & Time: Sunday, June 22, from 12:30 PM to 1:30 PM CDT
• - Location: Exhibit Hall, Poster Presentation Area 785P 12-B.

This session will not only share results but will also enhance understanding of how RGT-075 fits into current obesity management strategies, potentially offering a fresh avenue of treatment for those battling this prevalent condition.

Expansion of RGT-075 Development Program

Building on the momentum generated from the Phase 1 trials, Regor is currently advancing RGT-075 into a larger Phase 2b dose-finding trial known as COMO-1. This multicenter, randomized, double-blind, placebo-controlled study aims to evaluate multiple dosing regimens of RGT-075 over 36 weeks. Approximately 240 participants have enrolled in the study, highlighting the growing interest in effective obesity treatments.

In this ongoing trial, participants will receive once-daily doses of RGT-075, gradually increasing over the first 12 weeks. The primary goal of the COMO-1 trial is to determine the percentage change in body weight from baseline after 36 weeks of treatment. Additionally, the study aims to assess the safety and tolerability of the monthly titration scheme, alongside pharmacokinetics of RGT-075. Top-line results from this comprehensive study are anticipated by the end of 2025, intensifying excitement within both the scientific community and potential investors in biotech innovations.

About Regor Therapeutics

Headquartered in Cambridge, MA, with operations in Houston, San Diego, and Shanghai, Regor Therapeutics is at the forefront of clinical-stage biotechnology. The company prides itself on developing innovative, clinically differentiated medicines that address significant unmet medical needs in fields such as oncology, metabolism, and auto-immunity.

The advanced efficiency of Regor’s rCARDTM (Regor Computer Accelerated Rational Discovery) platform is a testament to its groundwork for rapid molecule prototyping and validation. This strategic approach has benefitted Regor significantly, allowing the firm to forge lucrative partnerships with top pharmaceutical players, including recent deals that underscore the efficacy of their treatment candidates.

To stay updated about Regor Therapeutics and its pioneering projects, visit www.regor.com.

For media inquiries, please reach out via the provided contact details.